7 results about "Anti tuberculosis" patented technology

Provided here are nucleic acid constructs containing a Mycobacterium tuberculosis genome comprising a mutation (such as a deletion) of the sigH gene (AsigH) and a mutation (such as a deletion) of at least one additional gene, and mutant Mycobacterium tuberculosis encoded by the nucleic acid constructs. Also provided are methods of making such nucleic acid constructs and Mycobacterium tuberculosis mutants, and uses thereof. The construct can stimulate an immune response against Mycobacterium tuberculosis in a subject, and can be used as live attenuated vaccines.

The present invention relates to novel rufamycin analogs that target the ClpC1 protease. The compounds of the present invention have antibacterial activity, e.g., with anti-tuberculosis properties, and are useful in the treatment of e.g. Tuberculosis.

The present invention is directed to a vaccine composition against a disease caused by Mycobacterium tuberculosis, said composition comprising at least four nucleic acids selected from the following groups: a. a nucleic acid encoding an Ag85A, Ag85B, or Ag85C antigen; b. a nucleic acid encoding a resuscitation promoting factor (Rpf) selected from the group consisting of: RpfA, RpfB, RpfC, RpfD and RpfE; c. a nucleic acid encoding a PE / PPE antigen selected from the group consisting of: PE5, PE13, PE15, PE29, PE31, PPE1, PPE2, PPE18, PPE20, and PPE68; d. a nucleic acid encoding a disease-reactivation-related antigen selected from the group consisting of: Rv1234 / MMAR_4207, and Rv0359 / MMAR_0678, wherein said vaccine composition comprises at least one nucleic acid from each of group a, b, and c; and wherein the nucleic acids are provided on one or more nucleic acids constructs.

The present application relates to the technical field of pharmacy, in particular to application of compound Diaporterpene C in preparation of mycobacterium tuberculosis tyrosine phosphatase inhibitor. The present application provides application of compound Diaporterpene C in preparation of mycobacterium tuberculosis tyrosine phosphatase inhibitor, the compound can significantly inhibit the activity of key virulence factor tyrosine phosphatase MptpA and MptpB of mycobacterium tuberculosis, can be used as tyrosine phosphatase inhibitor with MptpA and / or MptpB as target, and can be further developed as anti-tuberculosis drug. The compound shows good anti-tuberculosis activity by inhibiting pathogenic signal pathway of pathogenic bacteria, and has important clinical application potential and development value in tuberculosis treatment.

The invention relates to the technical field of biological medicines, and discloses application of an IGF1R (Insulin-like Growth Factor 1 Receptor) gene as an anti-tuberculosis target spot in treatment and / or diagnosis of tuberculosis. The IGF1R gene is related to the susceptibility of tuberculosis. The IGF1R gene is used for regulating a tumor-related pathway and a PI3K-Akt signal pathway, so that host-oriented anti-tuberculosis is realized. BEAS-2B cells are stimulated through PPD, it is proved that the IGF1R gene has susceptibility correlation with TB, the correlation between the IGF1R gene and a tumor-related pathway and a PI3K-Akt signal pathway and related key functional genes are determined, a new thought is provided for research on TB morbidity and tuberculosis susceptibility, and a foundation is laid for the IGF1R gene serving as a new target in TB diagnosis and treatment.

The invention relates to the technical field of biological medicine, in particular to application of salvianolic acid in preparation of an anti-tuberculosis drug. The invention provides application of salvianolic acid A or pharmaceutically acceptable salt thereof in preparation of the anti-tuberculosis drug, the molecular formula of the salvianolic acid A is C26H22O10, and the structural formula is shown in formula I. When the salvianolic acid A is applied to preparation of the anti-tuberculosis drug, a brand new material basis is provided for research and development of the anti-tuberculosis drug, damage of the drug to normal tissues of a human body is reduced, and the anti-tuberculosis drug can be applied to preparation of the anti-tuberculosis drug. Toxic and side effects are reduced. From the aspect of action mechanism, the salvianolic acid A has various biological activities such as inflammation resistance, oxidation resistance and immunoregulation, and can inhibit the growth and reproduction of mycobacterium tuberculosis and enhance the immune defense capability of the body to tubercle bacillus through the multi-target synergistic effect, thereby achieving the purpose of treating tuberculosis.

The invention belongs to the field of biological medicines, and provides an application of acetoacetic acid and derivatives thereof in preparation of medicines for treating or relieving hepatotoxicity caused by antituberculosis medicines. The hepatocytes formed by differentiation of human induced pluripotent stem cells are verified, and hydrazine is a metabolite with the strongest toxicity, so that the content of acetoacetic acid in the metabolite in the cells is reduced. Acetoacetic acid is one of main ketone metabolites in the ketone metabolism process, and cells can convert acetoacetic acid into acetoacetyl coenzyme A through succinyl coenzyme A: 3-oxo acid coenzyme A transferase. According to the invention, the OXCT1 gene in the human induced pluripotent stem cell is knocked out through CRISPR-cas9 and the human induced pluripotent stem cell is differentiated into the hepatocyte, so that the knockout of the OXCT1 gene increases the content of acetoacetic acid and reduces hepatic differentiation cell death caused by hydrazine.